ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.
